US drug regulator issues warning on certain multiple sclerosis drugs
The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may.
Health
Medical
Research
ADHD in US adults rises to 15.2% between 2020 and 2023: Research
US adults with attention deficit hyperactivity disorder (ADHD) rose from 10.6% to 15.2% between 2020 and 2023, and Covid-19 pandemic may be a.
Drugs
Health
Pharma
Daiichi Sankyo sets up robotic lab in US to speed up drug discovery
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.
Climate
Health
Medical
US to pull out from Paris Agreement that limits global warming
The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.
Health
Medical
Pharma
US to withdraw from WHO after an executive order from Donald Trump
The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19.
Drugs
Health
Pharma
AstraZeneca’s medicine to treat a type of breast cancer gets US nod
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs
Health
Pharma
US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
Drugs
Health
Pharma
Vertex, China’s Zai to develop, commercialise kidney disease drug
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.
Drugs
Health
Medical
Novo Nordisk, Valo expand pact to include obesity, diabetic drugs
Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.
Drugs
Medical
Pharma
WuXi Biologics sells global rights to cancer antibody to Candid for $925m
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.